» Articles » PMID: 38486236

Patient Interest in the Development of a Center for Ehlers-Danlos Syndrome/hypermobility Spectrum Disorder in the Chicagoland Region

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2024 Mar 15
PMID 38486236
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Ehlers-Danlos Syndromes (EDS) are a group of connective tissue disorders that are hereditary in nature and characterized by joint hypermobility and tissue fragility. The complex nature of this unique patient population requires multidisciplinary care, but appropriate centers for such care do not exist in large portions of the country. Need for more integrated services has been identified in Chicagoland, or Chicago and its suburbs. In order to explore and begin to address barriers to seeking appropriate care facing EDS patients in this region, we developed an online survey which we circulated through EDS social media groups for Chicagoland patients.

Results: Three hundred and nine unique respondents participated. We found that there exists a strong medical need for and interest in the development of a center in the region, and participants reported that, if made available to them, they would make extensive and regular use of such a facility.

Conclusions: We conclude that the establishment of a collaborative medical center specializing in the diagnosis and treatment of EDS, Hypermobility Spectrum Disorder, and related disorders in the Chicagoland area would greatly benefit patients by providing comprehensive care, alleviate the burden on overworked healthcare providers, and contribute to the sustainability of medical facilities.

Citing Articles

An evaluation of practices and policies used in genetics clinics across the United States to manage referrals for Ehlers-Danlos and hypermobility syndromes.

Boucher L, Nestler B, Groepper D, Quillin J, Deyle D, Halverson C Genet Med Open. 2025; 3:101960.

PMID: 39996015 PMC: 11849115. DOI: 10.1016/j.gimo.2024.101960.


The need for primary care providers in the clinical management of hypermobility spectrum disorders and ehlers-danlos syndrome: a call to action.

Black W, Black L, Goldstein-Leever A, Fox L, Pratt L, Jones J Rheumatol Int. 2024; 44(11):2273-2278.

PMID: 39110211 DOI: 10.1007/s00296-024-05676-4.

References
1.
Halverson C, Clayton E, Garcia Sierra A, Francomano C . Patients with Ehlers-Danlos syndrome on the diagnostic odyssey: Rethinking complexity and difficulty as a hero's journey. Am J Med Genet C Semin Med Genet. 2021; 187(4):416-424. DOI: 10.1002/ajmg.c.31935. View

2.
Knight D, Confiado S, Bruno K, Fairweather D, Seymour-Sonnier A, Jain A . Establishing an Ehlers-Danlos Syndrome Clinic: Lessons Learned. SN Compr Clin Med. 2022; 4(1):138. PMC: 9255530. DOI: 10.1007/s42399-022-01218-w. View

3.
Anderson L, Lane K . The diagnostic journey in adults with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. J Am Assoc Nurse Pract. 2021; 34(4):639-648. DOI: 10.1097/JXX.0000000000000672. View

4.
Clark C, Simmonds J . An exploration of the prevalence of hypermobility and joint hypermobility syndrome in Omani women attending a hospital physiotherapy service. Musculoskeletal Care. 2010; 9(1):1-10. DOI: 10.1002/msc.184. View

5.
Song B, Yeh P, Harrell J . Systemic manifestations of Ehlers-Danlos syndrome. Proc (Bayl Univ Med Cent). 2021; 34(1):49-53. PMC: 7785142. DOI: 10.1080/08998280.2020.1805714. View